The company will showcase these relationships, as well as new additions to its industry-leading offering of mass spectrometry (MS) and chromatography instruments, during the Human Proteome Organization (HUPO) Reconnect event, being held virtually November 15-19. “Proteomics research has the potential to expand our scientific understanding and uncover new biomarkers to meet unmet medical needs,” said Andreas Huhmer, senior director, life sciences research omics marketing, Thermo Fisher Scientific. “While there has been significant progress in our ability to perform advanced analyses such as single-cell and translational proteomics, there are still improvements needed in the efficiency and reproducibility of workflows. The agreements we’re announcing today will enable us to continue to deliver innovative proteomics solutions to customers with a goal to make these workflows accessible to everyone.”
Read more about this news here.
